Sector: Health Care
Director information for CG ONCOLOGY INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arthur Kuan | Chairman of the Board; Chairman and Chief Executive Officer | 35 | ["Founding Member of Ally Bridge Group","managed fund’s portfolio companies from January 2013 to July 2015","served on the IP Commercialization Strategy Committee at Moffitt Cancer Center since November 2017","served on the board of directors of Chunghwa Chemical Synthesis & Biotech since 2022","board of directors of Allied Industrial Corp., Ltd. from 2016 to 2023","M.S. in Biotechnology from Johns Hopkins University","B.A. in Biology from University of Pennsylvania"] | ["IP Commercialization Strategy Committee","compensation committee","audit committee"] | 2026 |
| Brian Liu | Director | 37 | ["Managing Member at Seven Fleet Capital since May 2025","Managing Director at Longitude Capital since 2018","Former Engagement Manager in the pharmaceuticals practice"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Brian Liu, M.D. | [] | ["Audit Committee"] | 2026 | ||
| Christina Rossi | Director | 50 | ["More than 25 years of global pharmaceutical and biotechnology experience","Interim Chief Executive Officer at Blueprint Medicines","Chief Operating Officer of Blueprint Medicines from 2022 until its acquisition by Sanofi","Chief Commercial Officer at Blueprint Medicines","Business Unit Head, North America, at Sanofi Genzyme","Vice President, MS Sales at Sanofi Genzyme","Vice President, MS Patient and Provider Services at Sanofi Genzyme","Healthcare consultant at Boston Consulting Group","Board member at Xilio Therapeutics, Inc."] | ["Compensation Committee"] | 2026 |
| James J. Mulé | Director | 73 | ["Associate Center Director for Translational Science at Moffitt Cancer Center","Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment","Director of Moffitt Cancer Center since 2003","served multiple tenures at the FDA since 1993","served at the National Cancer Institute"] | [] | 2026 |
| Leonard Post | Lead Independent Director | 73 | ["Over three decades of pharmaceutical R&D experience","Experience as Chief Scientific Officer at Vivace Therapeutics and Virtuoso Therapeutics","Worked at BioMarin overseeing gene therapy projects","Experience at LEAD Therapeutics, Onyx Pharmaceuticals, and Parke-Davis Pharmaceuticals","Advisor to Canaan Partners"] | ["Compensation Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Susan Graf | Director | 53 | ["Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC since May 2021","Former Chief Executive Officer of Akamara Therapeutics from August 2019 to May 2021","Former Chief Business Officer at Epizyme from April 2016 to September 2018","Former Principal Financial Officer at Epizyme from August 2017 to September 2018","Held Vice President position at NPS Pharma before acquisition by Shire in 2015","Nearly 18 years at Roche in leadership and executive positions","Chaired audit committee of Finch Therapeutics from April 2021 through March 2024","Board Chair at Finch Therapeutics from April 2022 through March 2024","Chaired audit committee of Aardvark Therapeutics since November 2024","Board member of Kaléo since December 2021","M.B.A. from the Stern School of Business at New York University","B.Pharm. from Purdue University"] | ["Audit Committee (Chair)","Nominating and Corporate Governance Committee","Audit Committee"] | 2026 |
| Victor Tong, Jr. | Director | 42 | ["Managing Director at Decheng Capital"] | ["Nominating and Corporate Governance Committee (Chair)","Audit Committee"] | 2026 |
